Virax Biolabs Group Limited
VRAX | NASDAQ
$2.50
+$0.19 (+8.23%)
At close: Sep 22, 2026, 4:00 PM ET
$2.50
$0 (0.00%)
After-hours:
Sep 22, 2026, 7:30 PM ET
Market Data
Market Cap $431.1K
Enterprise Value $-5.67M
Beta 1.36
Average Volume 1.76M
Shares Outstanding (Diluted) 604.66K
Shares Change YoY 575.58%
Institutional Ownership 9.25%
Exchange NASDAQ
ISIN KYG9495L1335
Price Performance
Price Change 1M -26.0%
Price Change 3M -40.3%
Price Change 6M -50.1%
Price Change YTD -75.9%
Price Change 1Y -85.1%
Price Change 3Y -97.4%
Price Change 5Y -99.9%
1M CAGR (ann.) -22.5%
1Y CAGR (ann.) -85.7%
5Y CAGR (ann.) N/A
All-Time CAGR -83.8%
Valuation
PE Ratio -0.14
Forward PE N/A
PEG Ratio -0.00
Forward PEG 0.00
PS Ratio 34.70
Forward PS 107.80
PB Ratio 0.06
P/FCF Ratio -0.09
P/Adj. FCF Ratio -0.08
P/OCF Ratio -0.12
EV/Sales -456.63
EV/EBIT 0.89
EV/EBITDA 0.94
EV/FCF 1.13
Earnings Yield -722.9%
FCF Yield -1169.3%
Adj. FCF Yield -1187.6%
Financial Health
Net Cash $6.49M
Total Debt $414.39K
Cash & Short-Term Investments $6.52M
Total Assets $8.32M
Current Ratio 9.97
Quick Ratio 9.90
Debt / Equity Ratio 0.05
Debt / EBITDA -0.07
Debt / FCF -0.08
OCF / Debt -11.55
Interest Coverage -96.86
Altman Z-Score -6.37
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin -1480.5%
Operating Profit Margin -51515.2%
EBITDA Margin -56151.4%
Net Profit Margin -52473.3%
FCF Margin -40576.6%
Adj. FCF Margin -41211.8%
SBC / Revenue 929.4%
SBC Impact (per share) -1.6%
Returns
Return on Assets -88.4%
Return on Equity -114.2%
Return on Invested Capital -100.0%
Return on Capital Employed -117.6%
Return on Tangible Assets -88.4%
Historical Growth (CAGR)
Revenue CAGR 3Y -50.1%
Revenue CAGR 5Y -36.9%
Revenue CAGR 10Y N/A
EPS CAGR 3Y 22.9%
EPS CAGR 5Y 20.8%
EPS CAGR 10Y N/A
FCF CAGR 3Y -47.9%
FCF CAGR 5Y -19.8%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 1
EPS Growth Next 3Y N/A
Revenue Growth Next 3Y N/A
Earnings Date Dec 1, 2026
EPS Estimate (next Q) -$1.75
EPS Growth Est (next Q) -85.7%
Revenue Est (next Q) $12.42K
Revenue Growth Est (next Q) 521.1%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $1
Price Target Upside -56.7%
Cash Flow
Operating Cash Flow $-4.79M
Free Cash Flow $-5.04M
Adj. Free Cash Flow $-5.12M
FCF Per Share -$19.98
OCF Per Share -$18.98
OCF/S Ratio -53775.8%
Income Statement
Revenue $12.42K
Gross Profit $7.69K
Operating Income $-6.4M
EBITDA $-6.05M
Net Income $-5.02M
EPS (Diluted) -$16.70
Revenue / Employee $477.81
Profit / Employee $-193.22K
Employees 26
Add to Watchlist
Select watchlists to add or remove VRAX